



uvmedico
IRELAND

UV Medico Ireland Limited
EII Investment Opportunity 2022

INFORMATION MEMORANDUM



UV Medico
Light that keeps us safe

UV Medico Ireland Limited
O'Brien Road, Carlow, Ireland
Phone: +353 599188138
Email: sales@uvmedico.ie
Web: www.uvmedico.ie

Strictly Private and Confidential

IMPORTANT NOTICE

This Information Memorandum ('IM') has been issued by UV Medico Ireland Limited (or 'the Company') with the assistance of its advisors and describes an investment into UV Medico Ireland Limited through the Employment and Investment Incentive Scheme ('EIS'). It is being delivered to parties who have expressed an interest in investing in the scheme.

The information contained herein does not purport to be comprehensive and is strictly for information purposes only. This Information Memorandum does not constitute an offer and shall not form the basis of any contract between the Company and any prospective investor. Prospective investors are advised to make their own independent commercial assessment of the information contained herein and obtain independent professional advice (including inter alia legal, financial and tax advice) suitable to their own individual circumstances, before making an investment decision, and only make such decisions on the basis of their own objectives, experience and resources.

Tax information contained herein is based on current understanding of the tax legislation in Ireland and the Revenue Commissioners' interpretation thereof. This information is provided by way of general guidance only and purports to be neither exhaustive nor definitive and is subject to change without notice. It is not a substitute for professional advice. You should consult your tax advisor about the rules that apply in your individual circumstances.

While all reasonable care has been given to the preparation of this IM, no warranties or representation, expressed or implied, are or will be given or liability accepted by the Company, its advisors or any affiliates, or its Directors or employees of the Company in relation to the accuracy, fairness or completeness of the information contained herein or any other written or oral information or opinions provided now or in the future to any prospective investors or their advisors and so far as permitted by law and except in the case of fraud by the party concerned, no responsibility or liability is accepted for the accuracy or sufficiency thereof, or for any errors, omissions or misstatements, negligent or otherwise, relating thereto.

An investment in the Company should only be considered by investors who are able to bear the economic risks of their investment for a medium to long term period of time and who can afford to sustain a total loss of their investment. The Company gives no undertaking to provide a prospective investor with access to any additional information or to update this IM or any additional information, or to correct any inaccuracies in it which may become apparent.

The Company reserves the right, without giving reason, at any time and in any respect, to amend or terminate the procedure for investing in the Company or to terminate negotiations with any prospective investor. The issue of this IM shall not be deemed to be any form of commitment on the part of the Company to proceed with any transaction with any prospective investor or any other party.

This IM has been made available on the express understanding that any written or oral information contained herein or otherwise made available will be kept strictly confidential and is only directed to the parties to whom it is addressed. No part of this document is to be reproduced without UV Medico Ireland Limited's written permission. This publication is solely for information purposes and does not constitute an offer or solicitation to buy or sell securities. This document has been prepared and issued by UV Medico Ireland Limited on the basis of publicly available information, internally developed data and other sources believed to be reliable.

COMPANY INFORMATION

CRO Number	712488
Registered Office	O'Brien Road, Carlow Co. Carlow R93 WN5X
Company Officers	Liam Byrne (Director) Paul O'Carroll (Secretary)
Bankers	AIB Bank
Accountants	P.A. McCormack & Co. Chartered Certified Accountants & Registered Auditors www.pamccormack.com
Tax Clearance Number	371769

Contents

EXECUTIVE SUMMARY	5
PROJECT DETAILS	6
BACKGROUND.....	6
THE PROMOTERS	8
THE PRODUCT	9
RISK FACTORS.....	11
THE MARKET AND INVESTOR OPPORTUNITY.....	13
FUNDING.....	15
FINANCIALS	16
EIIS SCHEME- HOW IT WORKS	17
PROCEDURE FOR APPLICATIONS.....	19
APPLICATION FORM.....	20
APPENDIX.....	23

EXECUTIVE SUMMARY

PROJECT BACKGROUND

UV Medico Ireland Limited is the exclusive distributor for UV Medico's human-safe Far UV-C light disinfection products across Ireland and the UK.

UV light has been effectively used in infection control for over 100 years. What is unique about UV Medico's Far UV-C products is that they are completely safe to use in occupied spaces- they are human and animal safe and will not cause damage to skin or eyes.

World Health Organisation Endorsement

Their products, which are endorsed by the World Health Organisation have been adopted across the globe for use across several application areas including medical, pharmaceutical, transport, business settings, food processing, agricultural, sports & entertainment as well as educational institutions.

THE MARKET OPPORTUNITY

The global UV disinfection equipment market is projected to grow from 2019 level of \$1.3 billion to \$5.7 billion in 2027 – this represents a compound annual growth rate of 17.1% per

annum.

Given the above, quite conservative, growth estimate – UV Medico Ireland Limited through their proven management team and unique technology solution are superbly positioned to serve this high growth market segment.

THE PRODUCT

CARE 222 is a new and one-of-a-kind disinfecting light technology which disinfects both air and surfaces while occupied by people. It inactivates both bacteria and viruses. Care 222 is not a stand-alone disinfecting system but is a key component in the very latest UV light disinfecting systems available.

FUNDING

It is intended to raise €1.5m through EII Initial Funding, the finance is to be used for launch into UK Market and further penetration into the Irish Market. These funds will be used for business development, expansion of the technical team, sales and marketing, partner development and operations. Projected Profit & Loss Accounts and Cash-flow Forecasts have been prepared for both the Irish Market and the UK Market

THE PROMOTERS

The promoting company is UV Medico Ireland Limited (www.uvmedico.ie) which is UV Medico A/S's (www.uvmedico.com) exclusive Irish and UK partner.

The team behind and driving UV Medico Ireland Limited:

Liam Byrne (CEO & Strategy)	Paul Duffin (Health Care and Strategy)
Colin Connolly (Financial Controller / Chartered Accountant)	Jason Sheehy (Market Development & Corporate Finance)
Cadi Lennon (Marketing Manager)	Steve Bertuzzi (Sales & Marketing Consultant UK)

FINANCIALS

Projected Profit & Loss Accounts and Cash Flow Forecasts have been prepared for the 5 years December 31st, 2027. for both the Irish and UK market.

	Sales	Cost of Sales	Net Profit	Net Cash Flow
5-year Totals	€46.2 mil	€26.2 mil	€6.0 mil	€5.6 mil

PROJECT RISKS

Unforeseen circumstances may result in delays or additional costs.

Revenue underperformance May delay exit.

EII SCHEME

Investors can invest in a Qualifying Company and under EII (Employment Investment Incentive) obtain generous tax allowances. Individual investors can obtain up to 40% tax relief (in year 1)

Investment	Total Input	Year 1 Tax Relief	Year 1 Net Investment Cost	Year 4 Share Redemption	% Return before CGT	CGT Tax Arising on Redemption	% Return after CGT
€10,000	€10,000	€4,000	€6,000	€11,000	83.3%	€330	78.3%

PROCEDURE FOR APPLICATION

See attached.

PROJECT DETAILS

BACKGROUND

UV Medico Ireland Limited is the exclusive distributor for UV Medico’s human-safe Far UV-C light disinfection products across the Island of Ireland and the UK.

UV light has been effectively used in infection control for over 100 years. What is unique about UV Medico’s Far UV-C products is that they are completely safe to use in occupied spaces- they are human and animal safe and will not cause damage to skin or eyes. This is all possible thanks to a patented technology developed by Japanese company ‘USHIO’. USHIO’s technology is called Care222, and this is what is used within UV Medico products.



Care222 is a new and one-of-a-kind disinfecting light technology which is endorsed by the World Health Organisation. It inactivates bacteria and viruses in the same manner as conventional ultraviolet sanitisers but can be used while people are present. Care222 is not a stand-alone disinfecting system but is a key component in the very latest UV light disinfecting systems available.

UV Medico, headquartered in Denmark are a team of business entrepreneurs, lighting technologists and scientific experts who gathered this technology in a small, compact, and low-maintenance Far UV-C lamp with a lifetime of 17 500+ hours. When turned on in intervals, this lifetime is extended, and the lamp can be used for years. The products are effective, safe, and affordable, with a performance comparable to 35 air changes per hour.



UV222TH

UV Medico’s standard model helps you make offices, medical installations and more, safe from bacteria and diseases.



Vehicle

Customized UV Medico lamps dedicated to the interior of ambulances and lifts:



Downlight

UV disinfection – now camouflaged in a neutral ceiling spot.



Pendant

Deeper and safer disinfection made possible, with an elegant design easily integrated into any space.





Industrial


Its IP66 rating offers protection wherever maximum durability is required.

In addition, there is a clearly defined product runway in development in areas such as medical and surgical device applications. These will likely come to market in the next 2-4 years post approvals processes.

The lamp inactivates up to 99.9% of viruses including SARS-CoV-2 and other pathogens in a few minutes without harming human skin or eyes.



UV222 emits Far UV-C light at a wavelength of 222 nanometres (nm) in harmless doses. The doses of Far UV-C light emitted by UV222 are in full compliance with local, European, and global guidelines.



Extensive research and development into the efficacy and safety of the UV Medico Far UV-C lamp was carried out by with support from Aarhus University, Columbia University and University of Boulder Colorado alongside some of Denmark’s largest hospitals- Aarhus University Hospital, National Hospital Denmark and Kolding Hospital.



‘We have measured the presence of bacteria in both periods and found that there are significantly fewer bacteria when the lamp is switched on’



Søren Helbo - Ward Doctor at the Lung Clinic in Aarhus University Hospital

UV Medico’s Far UV-C products have been adopted for use across several application areas including medical, pharmaceutical, transport, business settings, food processing, agricultural, sports & entertainment as well as educational institutions.

Distributed across the World, UV Medico has distributors across Europe, Australia, the USA and Africa. UV Medico Ireland Limited have spent the last 18 months researching the opportunity for the UK and Irish markets. They have identified specific niches that they believe represent significant near-term opportunities, as well as key industry experts and personnel that will be engaged once the EIS funding is in place. Funds are being raised to facilitate further expansion in the Irish market and entry into the UK market – funds will be used for product promotion, marketing, direct sales, reseller engagement, working capital and future development in the sector.

THE PROMOTERS

The promoting company is UV Medico Ireland Limited (www.uvmedico.ie) which is UV Medico A/S’s (www.uvmedico.com) exclusive Irish and UK partner.

The team behind and driving UV Medico Ireland Limited:

- Liam Byrne (CEO & Strategy)
- Paul Duffin (Health Care and Strategy)
- Colin Connolly (Financial Controller / Chartered Accountant)
- Jason Sheehy (Market Development & Corporate Finance)
- Cadi Lennon (Marketing Manager)
- Steve Bertuzzi (Marketing & Sales Consultant UK Market)

See Appendix 1 – The Team

UV Medico is a proven world leader, based in Denmark, in the provision of clean air and surface disinfection to some of the world’s largest and complex Medical, Healthcare, Pharmaceutical, Agri, Food, Sport and Hospitality industries. UV Medico Ireland is an approved partner in a worldwide network of distributors (<https://uvmedico.com/distributors/>)

THE PRODUCT

The pandemic has changed the way we think about infection prevention and control. In today’s world we have learnt that infection control is a must for all forward-thinking companies with occupational health concerns for their employees.

- UV light has been proven in infection control for over 100 years. What is unique about far UVC or UV222 is that it is safe to use in occupied spaces. The technology is endorsed by the World Health Organisation.

See Appendix 2- World Health Organisation



- UV222 has many applications that are not only safe, highly cost effective and practical, but disinfects both air *and* surface, while occupied by people.



Visualizing 222 nm pathogen inactivation



UV Medico’s UV222 device is fitted with intelligent software to optimize germicidal performance while continuously ensuring safety. Each unit is fitted with a patented filter from Ushio, Japan – this UVC filter ensures no side emissions above 222 nm which allows the safe use of these devices in occupied spaces. The UV Booth has been developed more recently and represents a huge opportunity in the clean room sector. This technology has already been installed in a leading Danish pharmaceutical organisation with substantial follow-up orders.



Cleanrooms

Pharma industries must follow strict cleanroom requirements to ensure the manufactured products are of high quality. This means the area of manufacturing must have the lowest possibility of particle presence. The number of contaminants in air and surfaces will affect the classification of the cleanroom. Controlling the environment and movement in the area can help achieve quality standards.

A person entering controlled areas carries foreign particles, being a potential source of contamination. The same is the case for raw materials and tools.

UV Medico has developed and adapted a solution for the pharmaceutical industry using UV222 technology: the UV222 Booth.

The UV Medico network has had multiple successes globally over the last 2 years, across a variety of sectors, including the following examples:

- Aarhus University
- Kolding Hospital Covid ward
- UEFA Futsal Euro 2022
- Beijing Winter Olympics 2022
- Tour de France
- European Handball Championship 2022
- Pharma Industry

See Appendix 3- Application Areas

Danish National Team free from Covid-19

“ We are very grateful to UV Medico for the UV222 solution. I believe it helped us go through the tournament with no outbreaks of Covid-19. ”




Morten Storgaard,
Doctor of the Danish National Team



MEN'S EHF EURO 2022
HANDBALL
HUNGARY - SLOVAKIA
13 - 30 JANUARY

The Irish promoting team has spent the last 18 months researching the opportunity for the UK and Irish markets. They have identified specific niches that they believe represent significant near-term opportunities. As well as identifying these opportunities the promoters have identified key industry experts and personnel that will be engaged once the EIS funding is in place.



RISK FACTORS

If you are in any doubt as to the action you should take concerning the contents of this document you should seek your own personal financial advice immediately from your stockbroker, bank manager, accountant, solicitor, or other independent adviser authorised or exempted under S.I. No. 60 of the European Communities (Markets in Financial Instruments) Regulations 2007 (as amended) or the Investment Intermediaries Act, 1995 (as amended) who specialise in advising on the acquisition of shares and other securities.

PROJECT RISKS

- Unforeseen circumstances may result in delays or additional costs
- Revenue underperformance may delay exit

In addition, prospective investors should note that this Information Memorandum contains several forward-looking statements, including statements of expectation as to matters which will occur in the future and estimates, and projections with respect of the Company's anticipated future performance and the market for its products. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or consequences of acquiring the Investor Shares to be materially different from any future results, performance or consequences expressed or implied by such forward looking statements. Factors which could cause actual results, performance or consequences that differ materially from those forward-looking statements in this Information Memorandum includes, among others, down turns in the economy or the global economy as a whole.

RISKS SPECIFIC TO EIIS INVESTMENTS

The Information Memorandum assumes that all Investors are Irish resident for tax purposes. Current legalisation and tax rates could change, with a consequent impact on Investors' investments. Prospective investors are advised to consult their own tax advisers before participating in this Placing.


While the risk factors listed below do not purport to be an exhaustive list or a complete explanation of all the risks involved in the Placing, the Directors consider that, as of the date of this Information Memorandum, the principal areas of risk for investors are as follows:

- Tax laws could come into force which could be unfavourable to the Company and/or the investors.
- No guarantee can be given that tax relief will be obtained on the investment or once it is given, that it will not be withdrawn by the Revenue Commissioners.
- While the Directors will endeavour to obtain the tax relief and EII forms as soon as possible after the investment they cannot guarantee the timing of such relief.
- Investors must have income in Ireland exceeding the amount of the investment in order to claim the tax relief.
- No compensation fund exists for Investors who lose all or part of their investment in this Company.
- Past performance should not be taken as an indication or guarantee of future performance; neither should simulate performance.
- Uncertainties arising from international financial and geo-political events in the international markets may have an impact on the value of the investment.
- The proposed investment in the Company is intended to be for a minimum of four years and it will not be possible to realise or transfer for at least that period.
- The Company might not have the financial resources to be able to redeem the EII Preference Shares after the four-year period.
- Prospective investors should carefully consider the risks and uncertainties involved in investing in unquoted companies. It may be difficult for investors to obtain reliable information about the value of such companies or the extent of the risks to which they are exposed and could result in the loss of some or all of the original investment.

THE MARKET AND INVESTOR OPPORTUNITY

The global UV disinfection equipment market is projected to grow from 2019 level of \$1.3 billion to \$5.7 billion in 2027 – this represents a compound annual growth rate of 17.1% per annum.

(<https://www.alliedmarketresearch.com/UV-disinfection-equipment-market>)



Given the above, quite conservative, growth estimate – UV Medico Ireland Limited through their proven management team and unique technology solution are superbly positioned to serve this high growth market segment.

It is through the service of this segment that a unique investment opportunity exists for EII Investors.

UV Medico Ireland Limited will provide full service to clients, including site survey, solution design, installation, maintenance and after care.

UV Medico Ireland Limited is using products which are fully regulatory compliant, medically endorsed, technologically advanced and proven in infection control for both air and surfaces. Having developed its products over many years the company is well placed to meet growing consumer demand and has a clear competitive advantage in the sector.


It is the proven track record of management in successfully promoting and scaling other enterprises, together with the unique competitive advantage in the endorsed products that provide both opportunity and comfort to investors.

Funds are being raised to facilitate further expansion in the Irish market and entry into the UK market – funds will be used for product promotion, marketing, direct sales, reseller engagement / sales, working capital future development in the sector.

Initial funding is in the amount of €1.5 million through EII (Enterprise Investment Incentive). EII offers investors the last significant tax break for investors in Ireland, relief of 40% can be obtained in year 1 based on company self-certification. Taking a tax break of 40% alone, provides the investor with a 67% return over 4 years. The tax break can be used against 'all income', including funds from ARF's (Approved Retirement Funds) – investors are currently struggling to maintain the current real value in their funds and EII provides them with a welcome opportunity.

FUNDING

It is intended to raise €1.5m through EII Initial Funding, the finance is to be used for launch into UK Market and further penetration into the Irish Market.



KEY EXPENDITURE AND TIMINGS

MARKETING AND BUSINESS DEVELOPMENT		-To drive scale
2023		€151,000
2024		€256,000

COUNTRY/ REGIONAL PARTNER DEVELOPMENT		-To speed up partner onboarding
2023		€50,000
2024		€150,000

ON-GOING CONSULTANCY SUPPORT		
2023		€125,000
2024		€300,000

FINANCIALS

Projected Profit & Loss Accounts and Cash-flow Forecasts have been prepared for the 5 years ended 31st December 2027 for both the Irish Market and the UK Market.

These forecasts have been prudently prepared, costs have been stressed upwards and revenues downward – the promoters are reasonably confident that net profit as projected will be exceeded

UV MEDICO IRELAND- FINANCIAL SUMMARY 5 YEAR PROJECTIONS

INCOME & EXPENDITURE	Total 2023	Total 2024	Total 2025	Total 2026	Total 2027	Overall Total
	€	€	€	€	€	€
TURNOVER	963,351	7,149,066	9,637,530	12,375,514	16,091,463	46,144,924
COST OF SALES	627,350	4,175,750	5,503,200	6,962,700	8,905,920	26,174,920
NET PROFIT/ (LOSS) (before tax)	(1,075,802)	284,074	1,072,591	2,078,720	3,654,928	6,014,512
CASHFLOW POSITION	2023	2024	2025	2026	2027	Total
	€	€	€	€	€	€
TOTAL NET CASHFLOW (Before Investments)	(1,143,442)	134,431	1,084,956	1,998,715	3,572,738	5,647,399

Further business continuity expenditure in terms of logistics and premises will be evaluated on an ongoing basis as growth evolves.

EIIS SCHEME- HOW IT WORKS

Investors can invest in a Qualifying Company and under EII (Employment Investment Incentive) – through generous tax allowances, individual investors can obtain up to 40% tax relief of the investment made in certain corporate trades.

An individual investor who has made an investment on or after the 1st January 2020 can claim relief on investments up to a maximum of €250,000 per year of assessment. Relief is obtained in Year 1 of the Investment.

Relief may be claimed on higher amounts of up to €500,000 per year, subject to additional conditions.

The investment is made in Ordinary Share Capital of the company, either directly or through a nominee company, to qualify the investment term is for a minimum period of 4 years from date of issue of share certificate.

The gross investment amount is allowable for CGT (Capital Gains Taxation) – CGT on the balance at 33%.

An investment of €10,000, after tax relief of 40% in year 1, has a net cost of €6,000. This represents an immediate return on investment of 67% over the 4-year term. Investment in the current year will qualify for relief, in most instances, against your 2022 preliminary taxation payment. On redemption further gains may be added to the return, based on company performance, subject to a maximum of 10% of gross investment amount.

Unlike some tax-based investments, relief is allowed against ‘total income’ which includes rental income and income from ARFs (Approved Retirement Funds).

INVESTMENT RETURN

The example below is for illustrative purposes only and is not a forecast, guarantee or expectation of investment outcome in UV MEDICO IRELAND LIMITED.

Investment return will be dependent on the performance of the project, however in any event will be capped at the Gross Amount Invested plus 10%.

Amount Invested in ‘A’ Ordinary Shares	€10,000
Term of Investment	4 years
Return after 4 years (Share Redemption)	€11,000

Investment	Total Input	Year 1 Tax Relief	Year 1 Net Investment Cost	Year 4 Share Redemption	% Return before CGT	CGT Tax Arising on Redemption	% Return after CGT
€10,000	€10,000	€4,000	€6,000	€11,000	83.3%	€330	78.3%

(In the above example we have ignored the annual Capital Gains Tax exemption of €1,270, as this may have been allocated against other gains.)

In the case married couples / civil partnerships, each spouse may invest up to the maximum amounts each and claim tax reliefs – on the assumption they have sufficient taxable income.

In the example above, it is assumed the investor has sufficient taxable income at the marginal 40% rate to offset against the amount invested.

(Prior to investing, individuals should obtain independent tax & legal advice – neither the promoters nor advisors can provide individual investors with any assurances in this regard.)

EII Funding – Amount and Purpose

Funding Target - €1,500,000

Minimum Amount - €500,000

The purpose of the funding is to meet the costs as set out below in respect of creating awareness, product promotion, staff technical training, re-seller technical training, sales training, working capital and entry costs into (i) the Republic of Ireland and (ii) the UK market.

It is estimated that Initial EII funding of €1,500,000 should be raised to provide funding for Irish and UK market development

Minimum Investment is €7,500 – Investors will be allotted Class ‘A’ Preference non-voting equity shares.

FURTHER INFORMATION ON RELIEF MECHANISM

Reliefs for Investments in Corporate Trades is contained in Part 16 of the Taxes Consolidation Act, link to Revenue Guidance is -

<https://www.revenue.ie/en/tax-professionals/tdm/income-tax-capital-gains-tax-corporation-tax/part-16/16-00-02.pdf>

PROCEDURE FOR APPLICATIONS

Participants should complete the Application Form on the following page and submit to UV Medico Ireland Limited, O'Brien Road, Carlow, Ireland on or before the Closing Date.

Completed Application Forms should be accompanied by a personal cheque or banker's draft, payable to UV Medico Ireland Limited for the amount of the subscription. (Direct Bank Transfers can also be facilitated as required)

UV Medico Ireland Limited reserves the right to close the application list at any time before 31st December 2022 and to reject any application in whole or in part at its absolute discretion (without obligation to give reasons therefore).

Applications to participate in the share subscription will be considered only if they are made on the application form contained herein. Any agreement purporting to amend or exclude or partly exclude the application of any term or condition of the share subscription shall be void. Only one application will be accepted from each applicant.

In order to ensure compliance with the provisions of the Criminal Justice (Money Laundering & Terrorist Financing) Act 2010, UV Medico Ireland Limited shall be required to establish the identity of each applicant to satisfy anti-money laundering requirements. Application forms must therefore be accompanied by:

- (i) a certified copy* of either the applicant's current passport or current driver's licence;
- (ii) an original or certified copy* of two different forms of proof of address.

Acceptable forms of proof of address are any two of:

- recent utility bill (electricity, gas, telephone or mobile phone);
- or
- bank statement.

Proofs of address cannot be more than 3 months old and must bear the name and address provided on the application form.

UV Medico Ireland Limited reserves the right to refuse to accept any application which is incorrectly presented or fails to comply with the provisions contained in the Memorandum and, in doing so, shall have no liability whatsoever to any applicant for interest or any resulting loss or damage.

All cheques will be lodged to UV Medico Ireland Limited's bank account on the day the share instrument is executed.

* certified copy means a document which contains a certification signed, stamped and dated by a solicitor, Commissioner for Oaths, Garda, Accountant or Bank Manager certifying that the copy document is a true copy of the original. UV Medico Ireland Limited can only accept original signatures on applications.

Applications will be accepted from 1st November 2022 until 31st December 2022.

Investors will be issued a €1 'A' Preference Share (Non-Voting) for every €1.00 invested. On acceptance of a completed application and once the subscription period has closed, UV Medico Ireland Limited will issue each investor with a share certificate which will confirm the investor's holding of shares in the Company.

APPLICATION FORM

PLEASE COMPLETE IN BLOCK CAPITALS

I attach a cheque/bank draft payable to (the Company)

in the amount of €

--

FORENAME(S)															
SURNAME															
ADDRESS															
PPS NUMBER												Date of Birth			
EMAIL ADDRESS															
PHONE NUMBER															

PLEASE TICK THE FOLLOWING BOXES TO CONFIRM YOUR AGREEMENT AND SO WE CAN PROCEED WITH YOUR APPLICATION.

- I wish to apply to make an investment in the Company in the amount stated above and I hereby undertake and agree to make the investment upon the terms of the Information Memorandum and the application form duly completed by me.
- I enclose a cheque/bank draft made payable to for the above-mentioned sum being the amount payable in full on application. I acknowledge that my cheque/bankers draft will be presented for payment on receipt.
- I confirm and acknowledge that no representation as to the accuracy or completeness of any information contained in the Information Memorandum or as to the availability of any tax relief or advantage is made or deemed to be made by the Company, and its agents or advisors. I acknowledge that the placing may not proceed, and, in such event, I acknowledge that I have no claim against any party.
- I acknowledge that all the terms and expressions in the Information Memorandum shall have the same meaning herein unless the context otherwise requires.
- In consideration of the Company agreeing to consider my application upon the terms and subject to the conditions of the Information Memorandum, I agree that this application shall be irrevocable and if accepted by the Company, shall constitute a contract between the Company and me.
- I agree that in respect of the EIS Preference shares for which my application is accepted in accordance with the terms of the Information Memorandum, notification to me in writing to the address set out above of the basis of allocation shall constitute full acceptance of my application on such basis.
- I hereby authorise you to forward to me confirmation of my investment and/or cheque for any refund monies to me by post at my risk to the address shown above.
- I acknowledge that any EIS Preference shares in respect of which my application may be accepted shall be issued and allotted to and registered in the name of in accordance with the terms set out below.
- I acknowledge that due to the anti-money laundering requirements pursuant to the Criminal Justice Acts, 2010 to 2018, that proof of identity will be required before this application form can be processed.

I hereby request and authorise the Nominee to hold in the name of the Nominee all and any EIS Preference shares in the capital of the Company issued to me pursuant to the Information Memorandum and all dividends and bonuses which may accrue from the EIS Preference shares and any other shares in the capital of the Company into which they may be converted and to hold them in trust and as Nominee for me, my personal representatives, successors and assigns on the below mentioned following terms:

1. the Nominee is authorised in its absolute discretion and without my prior consent:
 - a. Whenever notification of a right or entitlement is received in respect of the EIS Preference shares resulting from a bonus issue, dividend or split, the Nominee is entitled to exercise such right or entitlement in its total discretion as if it were the beneficial owner of the EIS Preference shares.
 - b. To execute in my name, whenever the Nominee deems it appropriate, and such ownership certificates and other documents as may be required to obtain the payment of income from the EIS Preference shares.
 - c. To rely on any communication, authority or document believed by the Nominee to be genuine and correct or to have been signed, sent, made or given by the proper person or persons and shall be entitled to consult legal advisers selected by the Nominee in respect of the EIS Preference shares in and to rely on their advice and to appear in any legal proceedings affecting the EIS Preference shares to which the Nominee may be made a party.
 - d. The Nominee shall have no liability of whatsoever nature for any loss suffered or incurred by me by delay in the actual receipt of notice by the Nominee of written instruction from me of notice of any payment, redemption or other transaction whatsoever regarding the EIS Preference shares in respect of which the Nominee is authorised to take any action.
 - e. The Nominee will be responsible for the performance of only such duties and obligations as are set forth herein or contained in written instructions from received by the Nominee and accepted by the Nominee. Such performance is subject to all applicable laws and regulations for any act or omission in connection herewith.
2. I hereby covenant with and undertake to the Nominee that I shall not require the Nominee to call for the transfer to me or as I may direct any or all of the EIS Preference share or shares held by the Nominee on my behalf (or any interest therein) for a period of 4 years and one day from the date on which the EIS Preference shares are issued and allotted to the Nominee or, thereafter, if to do so would require the Company to be re-registered as a public limited company.
3. I hereby agree to indemnify and to keep indemnified the Nominee and all its officers and employees against all and any losses, damages, costs and expenses which it or they or any of them may at any time in the future suffer or incur or by reason of any demand of whatsoever nature, howsoever described, that may be made on it or them or any of them arising out of or in any way connected with them by any reason of their acting under the above authorisation or any instructions from to it or to them or any of them save for any loss or damage arising solely out of any acts of fraud, negligence or wilful default of the Nominee or its officers or employees.
4. Without prejudice to any other mode of delivery, notices or other communications from the Nominee to me relating to the EIS Preference shares, notice shall be deemed to be sufficiently given or made when delivered but in any event not later than two days after dispatch (in case of mail) or 24 hours after dispatch (in the case of fax) addressed to me at the address herein given or such other address as may be specified by me by written notice received by the Nominee.
5. I confirm that for tax purposes I am resident in the Republic of Ireland and have income against which I can claim the tax relief.
6. I declare that I am not a US Citizen or a US Resident for tax purposes and I will advise both the Introducer and the Nominee if my status changes while I am an investor in the Fund. (Please contact if you may be a US Citizen or US Resident for tax purposes.)

I declare that I have read this Information Memorandum and application form and that I am fully aware of the time frame, risk factors (as set out in Section 11) and the costs entailed in investing in the Company.

Individual

Signature _____ Date _____

PLEASE NOTE THAT THE PROVISION OF THIS PRODUCT OR SERVICE DOES NOT REQUIRE LICENSING, AUTHORISATION, OR REGISTRATION WITH THE CENTRAL BANK OF IRELAND AND, AS A RESULT, IT IS NOT COVERED BY THE CENTRAL BANK OF IRELAND'S REQUIREMENTS DESIGNED TO PROTECT CONSUMERS OR BY A STATUTORY COMPENSATION SCHEME.

APPENDIX

APPENDIX 1 – THE TEAM

		<p>Liam Byrne, CEO with 30+ years’ strategic experience in a number of industries including Automotive, Food, Construction. Established own business in 2005.</p>
		<p>Paul Duffin, Entrepreneur with 25 years of experience in Automotive, Real Estate, Coffee and Private Health Clinics.</p>
		<p>Jason Sheehy, Entrepreneur with 30+ years’ experience running, Medical PPE, Technology, Food Retail. Formerly corporate finance partner with BDO.</p>
		<p>Colin Connolly, FC with 15+ years’ finance experience in multiple industries including Insurance, retail, Distribution & Medical practices</p>
		<p>Cadi Lennon, Marketing professional with background in journalism and media. 8 years’ experience across hospitality, education, and engineering sectors.</p>
		<p>Steve Bertuzzi, 27 years’ Snr Management, corporate Board and start up experience within Medical Technology and Devices, Hospital and Healthcare, Critical Care Solutions and services, plus 10 years UVC devices and Infection Prevention Technologies</p>

APPENDIX 2 – WORLD HEALTH ORGANISATION

World Health Organization Webinar: Disinfection using Ultraviolet Radiation 17/12/2021

Speakers:

Dr Ed Nardell- Professor of medicine and public health, Harvard University.

Dr Ewan Eadie-Head of Scientific Services at the Photobiology Unit & lead clinician for the Scottish Managed Clinical Network for Ultraviolet Phototherapy.

Dr Kenny Wood- Lecturer in the School of Physics & Astronomy, University of St Andrews

During the webinar, comparisons were made between different variants of air disinfection.

The secure Far-UVC technology used in our UV222 offered the best performance of all systems compared

Link to WHO webinar ‘Disinfection using Ultraviolet Radiation’ on Dec 17, 2021:

<https://who.zoom.us/rec/share/jJ-g1XfEdxMHIE9UaihXiFZ8fQvDLtrjofThW9QpH3m0dgdLxsRKIZHt0pWpJtUC.VXXhGvIX4EvLX41W>

with Passcode: 0@wQtVC\$

APPENDIX 3- APPLICATION AREAS

<p>Healthcare Since the COVID-19 pandemic, increasing attention is being paid to vulnerable patients in hospitals and clinics. Infection controls in healthcare environments rely on the use of protective equipment and personal hygiene which are both dependant on human behaviour.</p> <p>Far UV-C light has been identified as an efficient method to decrease the microbial burden on closed spaces and is suitable to operate in the presence of people. This makes Far UV-C light an apt solution for waiting rooms, operating rooms, patient rooms and dental surgeries.</p> <p>UV Medico have also developed the ‘UV222 Vehicle’ product which is suitable for use in ambulance cabins to reduce bacteria and viruses.</p>	<p>Cleanrooms (Pharmaceutical & Other) UV-C light disinfection systems are installed in the pharmaceutical industry at several points throughout the production process. Some examples are water treatment, air and tool disinfection.</p> <p>UV Medico has developed and adapted a solution for the pharmaceutical industry using UV222 technology: The UV Booth.</p> <p>The UV Booth can help maintain the established limits for microbial contamination by disinfecting gowned personnel right at the entrance of manufacturing areas.</p>
<p>Business & Entertainment Industries such as businesses with office workers, hospitality, entertainment, and sports were heavily affected by the COVID-19 pandemic and are now recovering slowly.</p> <p>Most of the infection countermeasures are based on human behaviour, such as the use of facial masks or keeping social distances. The implementation of these types of measures is particularly challenging in venues where the traffic of people is dense, and space is limited.</p> <p>UV Medico’s UV222 disinfection lamps can be used to protect employees, customers, and spectators in these industries where a large number of people are gathering.</p>	<p>Food Industry (Meat, Fruit, Vegetables) UV light disinfection improves food safety, prolongs shelf-life, prevents food-borne illnesses and controls insects. It is also a good alternative to chemicals in the food industry since it does not generate any residues.</p> <p>UV light disinfection can be used in several areas including production areas and packing areas and can yield benefits for meat processing, dairy, or fruit and vegetable industries.</p>
<p>Farming & Animal Health UV light disinfection provides many benefits to the swine, poultry, bovine, and equine industries.</p> <p>UV light disinfection has been successfully tested and proven to inactivate several animal viruses and is safe for use in the presence of animals.</p> <p>Biocontainment measures are common practices to avoid the spread of infections in farms, like the isolation of ill animals.</p> <p>UV222 Far UV-C lamps can be perfectly integrated in sanitation and containment procedures.</p> <p>The spread of infectious disease can also occur in veterinary hospitals and clinics. Pathogens can be transmitted among animals or from animal to humans. Studies have shown the benefit of supplementing manual disinfection with UV light.</p>	<p>Transport The pandemic has had a devastating impact on airports, train station and other transport stations.</p> <p>The sector is studying solutions to mitigate the risk of infection and increase confidence among passengers. The use of germicidal Far UV-light is emerging due to its efficacy to kill bacteria and suitability to be used in occupied spaces.</p> <p>UV Medico’s ‘UV222 Vehicle’ product can be installed in several transport vehicles including buses and shuttles to protect passengers.</p>

Full applications booklet available on request